Results 81 to 90 of about 20,809 (211)

Temporal Dilution: Chemotherapy, Capitalism, and the Making of Cancer Time in Colombia

The Journal of Latin American and Caribbean Anthropology, Volume 31, Issue 4, December 2026.
ABSTRACT Through the ethnographic case of a man undergoing chemotherapy for prostate cancer at a hospital in Colombia, this article examines how chemotherapy schedules make toxicity clinically manageable while imposing rhythms that many patients cannot sustain. It develops an analytic framework centered on three interrelated temporal dynamics: temporal
Camilo Sanz
wiley   +1 more source

Skin Toxicity Due to Mercaptopurine in Maintenance Therapy Among Children With Acute Lymphoblastic Leukemia

, 2023
Mercaptopurine is a crucial component in the treatment of acute lymphoblastic leukemia. It is associated with toxicities that can delay treatment. Mercaptopurine is metabolized into 6-thioguanine nucleotides and 6-methylomercaptopurine nucleotides (6MMPN)
Flatt, Terrie, Terrie Flatt, Higgerson, Kayeleigh, Kayeleigh Higgerson   +3 more
core   +1 more source

Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus

Arthritis Care &Research, Volume 78, Issue 11, Page 1640-1649, November 2026.
Objective Individuals with systemic lupus erythematosus (SLE) can accumulate functional status (FS) impairment. We evaluated the association between neighborhood socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), and FS in a national SLE sample.
Baljeet Rai, Jessica Fitzpatrick, Jing Li, Eric Roberts, Patricia Katz, Laura Plantinga, Gabriela Schmajuk, Jinoos Yazdany   +7 more
wiley   +1 more source

Gold Nanoparticles Enhance the Anti-Leukemia Action of a 6-Mercaptopurine Chemotherapeutic Agent

, 2016
6-Mercaptopurine and its riboside derivatives are some of the most widely utilized anti-leukemic and anti-inflammatory drugs. Their short biological half-life and severe side effects limit their use.
Paul Podsiadlo (1990147), Vladimir A. Sinani (2459356), Joong Hwan Bahng (1443691), Jungwoo Lee (433946), Nadine Wong Shi Kam (2398273), Nicholas A. Kotov (534991)   +5 more
core   +1 more source

Pharmacogenomics in Cancer Treatment: Challenges and Opportunities in African Settings

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Cancer incidence in Africa is projected to reach 2.1 million new cases annually by 2040. Current treatment guidelines remain largely based on pharmacogenomic data predominantly from European and Asian genetic profiles, potentially compromising safety and efficacy in African patients.
Ntombikhona Fortunate Maphumulo, George Rebello, Veron Ramsuran   +2 more
wiley   +1 more source

Complementary and Alternative Medicine: Impact of Consciousness Energy Healing Treatment on the Physicochemical and Thermal Properties of 6-Mercaptopurine [PDF]

, 2018
6-Mercaptopurine is a thiopurine-derivative antimetabolite, which is used for the treatment of cancer, ulcerative colitis, Crohn’s disease, and autoimmune diseases.
Jana, Snehasis, Trivedi, Dahryn, Trivedi, Mahendra Kumar, Branton, Alice, Nayak, Gopal   +4 more
core   +1 more source

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial

Cancer, Volume 132, Issue 21, 1 November 2026.
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Arnaud Pigneux, Pierre‐Yves Dumas, Marc Bernard, Norbert Vey, Audrey Bidet, Ariane Mineur, Aline Schmidt, Martin Carré, Mario Ojeda, Sarah Bertoli, Anne Banos, Pierre Peterlin, Romain Guièze, Yohan Desbrosses, Gabrielle Roth Guepin, Célestine Simand, Thibaut Leguay, Emmanuel Gyan, Eric Jourdan, Jean‐Philippe Vial, Tony Marchand, Yosr Hicheri, Marie C. Béné, Jean Francois Hamel, Christian Récher   +24 more
wiley   +1 more source

Clinical Functional Assignment of TPMT and NUDT15 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1427-1437, November 2026.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) TPMT/NUDT15 Pharmacogene Curation Expert Panel (PCEP) conducted a comprehensive review of clinical, laboratory, and computational evidence to determine the clinical function assignments for TPMT and NUDT15 star alleles.
Bailey M. Tibben, Maud Maillard, Victoria M. Pratt, Ann M. Moyer, Debbie M. Figueroa, Michelle Whirl‐Carrillo, Andrea Gaedigk, Gabriele Stocco, Matthias Schwab, Kelly E. Caudle, Jun J. Yang   +10 more
wiley   +1 more source

Pharmacogenetic variants and treatment-related toxicity during consolidation therapy in a child with Down syndrome-associated acute lymphoblastic leukemia: a case report

Pediatric Hematology Oncology Journal
Background: Children with Down syndrome-associated acute lymphoblastic leukemia (DS-ALL) are vulnerable to chemotherapy-related toxicity, including methotrexate toxicity.
Al-Motassem Yousef, Abrar Al-Sheikh, Daniah Alshamaseen, Rand Farhad, Mohammed Zawiah, Taha Kadi   +5 more
doaj   +1 more source

Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Purpose To characterize cancer treatment during pregnancy and maternal and infant outcomes among women with cancer identified during pregnancy in Japan. Methods In this descriptive cohort study, we used mother‐infant linkage data from the JMDC claims database from 2005 to 2024.
Masami Tsuchiya, Tomofumi Ishikawa, Takamasa Sakai, Satoko Hori, Taku Obara   +4 more
wiley   +1 more source